To appraise the clinical and cost effectiveness of tisagenlecleucel-T within its marketing authorisation for previously treated B-cell acute lymphoblastic leukaemia in people aged 3 to 21 at initial diagnosis.
 
Status Proposed
Process STA
ID number 1167

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2017 - 14 December 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance